Exjade One Year Experience Dr Khawla Belhoul Director Thalassemia Center 9 Th February 2008.

Slides:



Advertisements
Similar presentations
Iron Overload in Chronic Anaemias Dick Wells MD, DPhil, FRCPC Director, Crashley Myelodysplastic Syndrome Research Laboratory Odette Cancer Centre.
Advertisements

Iron Overload in Chronic Anaemias Dick Wells MD, DPhil, FRCPC Director, Crashley Myelodysplastic Syndrome Research Laboratory.
Introduction Medication non adherence ( noncompliance) remains a major problem. You have to assess and treat adherence related problems that can adversely.
1 Rash and Low T2* MRI in a Paediatric Thalassaemia Patient.
Clinical Case: Managing Iron Overload in a Patient with Transfusion- Independent Thalassaemia Intermedia Ali T. Taher, MD Professor Department of Internal.
Slide 1 of 16 Dose Titration in a Patient with Myelodysplastic Syndromes.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
TMC125 Safety and Tolerability: 24-week Results of the Pooled DUET-1 and -2 Trials R Haubrich, M Schechter, S Walmsley, M Peeters, M Janssens, G De Smedt.
Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE National Trends in the Prescribing of Anti-Hypertensive Medications Jun Ma, MD, PhD Research.
Managing Iron Overload in Beta Thalassemia Major: Focus on Cardiac Iron Ali Taher, MD American University of Beirut Lebanon.
Dexmedetomidine vs Midazolam for Sedation of Critically Ill Patients A Randomized Trial Journal Club 09/01/11 JAMA, February 4, 2009—Vol 301, No
1 British Guideline on the Management of Asthma BTS/SIGN British Guideline on the Management of Asthma, May 2008 Introduction Diagnosis Non-pharmacological.
Unit 5: IPT Isoniazid TB Preventive Therapy
BY ZIONE MAJAWA CHINOKO St. John of God College of Health Sciences, Mzuzu.
©2007 RUSH University Medical Center Hyperuricemia in adolescents with primary hypertension: how and when to intervene? Farahnak Assadi, M.D. Professor.
Rapivab™ - peramivir injection
Michael Dickinson, Haematologist
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
Factors Affecting Drug Activity Chapter 11 Pages
Noncompliance with Iron Chelation Therapy in an Adolescent with Thalassaemia Major Adlette C. Inati, MD Head, Division of Pediatric Hematology-Oncology.
Asthma Management Fine Tuning  Maximum control with minimum medication  Start with mild asthma and work up the scale (BTS/SIGN 2004)
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 11 Drug Therapy in Geriatric Patients.
Abstract Results Objectives Results Conclusions Background Methods V-1637 Background-At the CORE center in Chicago, despite an on-site hepatitis clinic.
LIFESTYLE INTERVENTION You CAN’T change where you came from…….. You CAN change where you are going……
Improving the Quality of Physical Health Checks
Quality of Life and Depression as Determinants of Treatment Adherence in Hypertensive Leonelo E. Bautista 1 ; Paul Smith 2 ; Cynthia Colombo 2 ; Dennis.
Efficacy and Safety of Deferasirox (Exjade®) during 1 Year of Treatment in Transfusion-Dependent Patients with Myelodysplastic Syndromes: Results from.
Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group,
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study) Lambers Heerspink,
Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee February 26 & 27, Overview Isotretinoin Pregnancy Exposures:
Dose Interruption/Reduction of Tyrosine Kinase Inhibitors in the First 3 Months of Treatment of CML Is Associated with Inferior Early Molecular Responses.
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
Vol 115, No. 3, pp , March 2007
Mariane de Montalembert, MD
X-Linked hypophosphatemic rickets (XLH), caused by mutations in PHEX, is the most common inherited disorder of renal phosphate wasting. The PHEX mutation.
The multiregional Italian Thalassemia Registry: patient’s population changes and related iron chelation approach Laura Mangiarini 1 R. Padula 1, D. Bonifazi.
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 2 ARBITER-2 Trial Presented at The American Heart Association Scientific.
The Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial ONTARGET.
CE-1 Exjade ® (deferasirox; ICL670) Efficacy and Safety Peter Marks, MD, PhD Senior Director, Clinical Development Novartis Pharmaceuticals Corporation.
The Diabetic Retinopathy Clinical Research Network Effect of Diabetes Education During Retinal Ophthalmology Visits on Diabetes Control (Protocol M) 11.
Dasatinib Compared to Imatinib in Patients with Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase (CML-CP): Twelve- Month Efficacy and Safety.
Carl P. Walther*, Amber S. Podoll*, Kevin W. Finkel* *The University of Texas Health Science Center at Houston Citrate Toxicity During CRRT After Massive.
A. Bazrafshan, MD Felloweshipe of Pediatric Hematology-Oncology Shiraz University of Medical Science Shiraz – Iran
1 Pulminiq™ Cyclosporine Inhalation Solution Pulmonary Drug Advisory Committee Meeting June 6, 2005 Statistical Evaluation Statistical Evaluation Jyoti.
CR-1 Candesartan in HF Benefit/Risk James B. Young, MD Cleveland Clinic Foundation.
C-1 Safety Results S. aureus Bacteremia and Endocarditis Study Gloria Vigliani, M.D. Vice President, Medical Strategy Cubist Pharmaceuticals.
1 Joint NDAC/EMDAC Meeting January 13, 2005 Mevacor TM Daily 20 mg Tablets Rx-to-OTC Switch Daiva Shetty, M.D. Division of Over-the-Counter Drug Products.
Thalassemia Center 1 Iron Overload in Chronic Anaemias.
Case 2 A 23-year old Indian young man Homozygous Beta-Thalassemia Major Diagnosed at the age of 6 months. On regular transfusion every 4 weeks since that.
Presented by : Fawziya Alyafei ped endocrine fellow ped endocrine fellow Department of Pediatrics Endocrinology and Hematology Hamad Medical Center, Qatar.
Journal Club Neuropsychological effects of levetiracetam and carbamazepine in children with focal epilepsy. Rebecca Luke 2/9/2016.
Opiate Therapy in Chronic Cough Alyn H. Morice, Madhav S. Menon, Siobhan A. Mulrennan, Caroline F. Everett, Caroline Wright, Jennifer Jackson and Rachel.
Risk Factors for Linezolid-Associated Thrombocytopenia in Adult Patients Cristina Gervasoni Ospedale Luigi Sacco, Milano.
At least one mobile phone will ring during a meeting or concert Anything that can go wrong will go wrong.
Hepatitis B virus infection in renal transplant recipients
Nephrology Journal Club The SPRINT Trial Parker Gregg
Acetylcysteine for Acetaminophen Poisoning
Table 1: Table 2: Non Therapeutic Angiograms in Acute Ischemic Stroke Patients Being Considered for Endovascular Treatment Does not Adversely Affect Patient.
No cirrhosis or compensated cirrhosis** No HBV or HIV co-infection
Drug Therapy in Geriatric Patients
Module 4: Role Playing and Case Discussions
Controlled drug release
Anticonvulsants: Valproic acid
The Diabetic Retinopathy Clinical Research Network
OA.
Phase 2 Treatment Naïve Injection Drug Use
Major classes of drugs to reduce lipids
Tapering and Discontinuing Chronic Opioid Therapy
Late-Breaking Data on LDL-C Reduction
Presentation transcript:

Exjade One Year Experience Dr Khawla Belhoul Director Thalassemia Center 9 Th February 2008

The Aim of This Presentation Is to present our experience with Exjade (Deferasirox or ICL670) in the context of 1.Effects on serum Ferritin in chronically transfused patients who had received Desferoxamine earlier. 2.Side effects and patients tolerance to the drug 3.Effects on Serum Creatinine and liver Transaminases 4.Improving patients quality of life 5.Other side observations

 N=135  > 12 months taking Exjade  Transfusion-dependent (Thalassemia Major) with ≥ 100 ml/kg cumulative prior PRBC  Prior DFO therapy at an average daily dose of = 40mg/kg/day  Average starting S. Ferritin =2353mg/dl  Exjade dose was prescribed according to FDA approved prescribing information  Exjade 20 to 30 mg/kg/day for 1 year  The youngest patient was 4 yr old & the oldest was 38 yr old Exjade One Year Experience at Thalassemia Center Dubai

Exjade One Year Experience at Thalassemia Center Dubai

95 Patients (71%) were ≤18 yr Exjade One Year Experience at Thalassemia Center Dubai 47% 24% 29%

Exjade One Year Experience at Thalassemia Center Dubai

Exjade One Year Experience at Thalassemia Center Dubai

Baseline Serum Ferritin ≤ 2000mg in 60% 12.5% 27.5% 60% Exjade One Year Experience at Thalassemia Center Dubai

Exjade Staring dose was 20mg /kg /day Dose increment was slow for the first 4 months because of frequent initial supply interruptions The supply was constant and adequate for the last 6 months Exjade Average Dose in the Last 6 months was 26mg/kg/day Max. dose achieved was 32 mg/kg/day

Average Dose (mg/kg/day) in the Last 6 months =26mg/kg Max. dose = 32 mg/kg/day Exjade One Year Experience at Thalassemia Center Dubai Average Dose in mg/kg/day NO. of patients

Low Baseline Ferritin <= Medium Baseline Ferritin 2000 to High Baseline Ferritin >= Exjade One Year Experience at Thalassemia Center Dubai Serum Ferritin remained static at an average Exjade dose of 26mg/kg/day compared to earlier average Desferal dose of 40 mg/kg /day..

Exjade One Year Experience at Thalassemia Center Dubai The effect on serum Ferritin was consistent whatever the initial serum Ferritin.

Exjade One Year Experience at Thalassemia Center Dubai The absolute change in serum Ferritin was dose dependent and started to be negative as we moved toward higher doses.

Exjade One Year Experience at Thalassemia Center Dubai Serum Ferritin remained static at an average Exjade dose of 26mg/kg/day compared to earlier average Desferal dose of 40 mg/kg /day. Significant reduction in serum Ferritin in chronically transfused patients on Exjade was commonly observed with an average daily dose equal or above 30mg/kg daily Serum Ferritin is reliable at low and normal levels, but loses accuracy as the iron load rises. Many factors independent from iron stores, may significantly alter the serum Ferritin concentration.

S. Creatinine Normal Values It depends on muscle mass. A normal value is mg/dL for men and 0.6 to 1.0 mg/dL for women. It is important to take into account serum creatinine trend rather than isolated values. A Creatinine of 1.0mg/dL might be normal or might be abnormal if it has recently increased from 0.6 to 1.0 mg/dL.

The P value is Exjade One Year Experience at Thalassemia Center Dubai Serum creatinine rise above baseline was observed in almost all the patients but remained within normal range. The consistency in Serum creatinine rise was statistically Significant (P value = )

S. Creatinine rise N=135 Exjade One Year Experience at Thalassemia Center Dubai

S. Creatinine rise N=135 Exjade One Year Experience at Thalassemia Center Dubai

S. Creatinine rise was frequent. S. Creatinine rise was often transient. Serum creatinine rise > 30% at 2 consecutive readings post baseline was higher among our patients compared to the internationally released data. But less patients required dose interruption because of sustained creatinine increase. Paediatric age group and those with law starting serum Ferritin appeared to be more liable to creatinine rise. The Creatinine elevations remained within the normal range Significant or persistent rise reverted to baseline once treatment temporarily adjusted or stopped. None of the patients needed to be excluded from the treatment because of sustained Creatinine rise. None Developed renal failure Exjade One Year Experience at Thalassemia Center Dubai

Exjade One Year Experience at Thalassemia Center Dubai

Exjade One Year Experience at Thalassemia Center Dubai

Exjade One Year Experience at Thalassemia Center Dubai

Action% Treatment was discontinued in only one patient because of drug fever 0.75% Treatment was continued in 134 out of 135 patients 99.25% Exjade One Year Experience at Thalassemia Center Dubai

Causes of Low Neutrophils ’ Count observed in 5 patientsNo. Hypersplenism2 Interferon & Rebavirin therapy for Hepatitis C2 Hydroxyurea, count improved after stopping it1 Exjade One Year Experience at Thalassemia Center Dubai

In 30% Who Completed Annual Tests ENTNil Ophthalmic Nil Echo*Nil Exjade One Year Experience at Thalassemia Center Dubai *NO INCREMENT OR DETERIORATION OBSERVED IN EF

Patients’ Satisfaction

Patients’ Satisfaction Questionnaire

Patients’ Satisfaction I was troubled by nausea and I was finding it difficult to go to sleep in the beginning but after few weeks I felt normal and I enjoyed being free from daily injections. The taste wasn't terrible but it took 15 MINUTES to dissolve this stuff!! As much as I'm complaining - it's still much better than 12 hours/night Desferal. It doesn’t taste good but taste doesn’t matter, it’s a hundred times better than poking yourself at night.

Patients’ Compliance Exjade introduction appeared to have improved our patients adherence to medication……….

Adherence to chronic pharmacologic therapy is always challenging. Chelation adherence is an important issue in the course of treatment of patients with Thalassemia major. The effect of patients’ education and motivation was thoroughly investigated among patients with many other chronic disorders, but was never tested among Thalassemia Major patients..

Method  40 Thalassemia major patients randomly selected, regardless of the type of iron chelator used.  Age was 10years and above.  These patients were subjected to compliance improvement project.  Improvement in compliance was assessed by observing the effect on serum Ferritin.

These patients were subjected to intensive education for 6 weeks (2 visits ) in the form of  Self-compliance assessment scale  Compliance assessment scale by doctors, social worker and nurses  Extensive education Health care provider intervention tool Group PowerPoint presentation and discussion on iron overload and iron chelator use. Group Round table discussions. Method

 The patients were also called every other week by phone.  The education stopped at 6 weeks and patients Serum Ferritin trend was observed for the following 10 weeks.

Doctor,nurse and social worker intervention tool

Patients’ Compliance

Compliance Improvement Project Intensive education period Intensive education stopped

Compliance Improvement Project

Intensive education period Intensive education stopped

Serum Ferritin declined while on intensive education irrespective of the chelating agent used. Serum Ferritin started to rise again once intensive education was interrupted irrespective of the chelating agent used. Causes of noncompliance were also studied among the same group of patients intensively

Causes of Non-compliance to Desferal

Causes of Non-Compliance to Exjade

Non-Compliance to Iron Chelation CAUSE EXJADEDESFERAL Forgetting 38.7%30.7% Inconvenience 9.7%46.1% Nil 32.2%7.7% ? ?

– Serum Ferritin remained static at an average dose of 25mg/kg/day compared to earlier average Desferal dose of 40 mg/kg /day – Exjade Was generally well tolerated – Mild Creatinine elevations, skin rash and mild gastrointestinal side effects were the commonest adverse experiences – Serum creatinine rise > 30% at 2 consecutive readings post baseline was higher among our patients – But less patients required dose reduction or interruption because of sustained creatinine increase – Paediatric age group and those with law starting serum Ferritin appeared to be more liable to creatinine rise. – The Creatinine elevations remained within the normal range – Side effects appeared to be potentially related to excessive and rapid chelation – No cases of arthropathy, or agranulocytosis – No renal failure – No deaths Exjade One Year Experience at Thalassemia Center Dubai Summary

Exjade One Year Experience at Thalassemia Center Dubai Summary Patient adherence to medical therapy has been called “the next frontier in quality improvement.” Exjade introduction appeared to have improved our patients adherence to medication. Without effective patients’ education and motivation, the benefits of such valuable and expensive drug can simply be wasted.